Apotea (APOTEA) - Net Assets
Based on the latest financial reports, Apotea (APOTEA) has net assets worth Skr962.80 Million SEK (≈ $103.61 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr2.23 Billion ≈ $239.53 Million USD) and total liabilities (Skr1.26 Billion ≈ $135.92 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. For live market cap and overall valuation, see Apotea stock valuation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr962.80 Million |
| % of Total Assets | 43.26% |
| Annual Growth Rate | 26.13% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 615.76 |
Apotea - Net Assets Trend (2021–2025)
This chart illustrates how Apotea's net assets have evolved over time, based on quarterly financial data.
Annual Net Assets for Apotea (2021–2025)
The table below shows the annual net assets of Apotea from 2021 to 2025. See how leveraged is Apotea's balance sheet to measure how much of total assets are equity-financed.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr859.90 Million ≈ $92.54 Million |
+1402.27% |
| 2024-12-31 | Skr57.24 Million ≈ $6.16 Million |
+36.16% |
| 2023-12-31 | Skr42.04 Million ≈ $4.52 Million |
-88.16% |
| 2022-12-31 | Skr355.00 Million ≈ $38.20 Million |
+4.49% |
| 2021-12-31 | Skr339.76 Million ≈ $36.56 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Apotea's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 156.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr832.60 Million | 98.65% |
| Common Stock | Skr500.00K | 0.06% |
| Other Comprehensive Income | Skr-3.80 Million | -0.45% |
| Other Components | Skr14.70 Million | 1.74% |
| Total Equity | Skr844.00 Million | 100.00% |
Apotea Competitors by Market Cap
The table below lists competitors of Apotea ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nanjing Hongbaoli Corp Ltd
SHE:002165
|
$830.62 Million |
|
Annexon Inc
NASDAQ:ANNX
|
$830.68 Million |
|
Archicom S.A.
WAR:ARH
|
$830.71 Million |
|
India Glycols Limited
NSE:INDIAGLYCO
|
$831.06 Million |
|
Suning Universal Co Ltd
SHE:000718
|
$830.40 Million |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
$830.31 Million |
|
China Union Holdings Ltd
SHE:000036
|
$829.91 Million |
|
Shinyoung Securities Co. Ltd.
KO:001720
|
$829.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Apotea's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 55,368,000 to 844,000,000, a change of 788,632,000 (1424.3%).
- Net income of 228,700,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 3,602,000.
- Other factors increased equity by 563,534,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr228.70 Million | +27.1% |
| Other Comprehensive Income | Skr-3.60 Million | -0.43% |
| Other Changes | Skr563.53 Million | +66.77% |
| Total Change | Skr- | 1424.35% |
Book Value vs Market Value Analysis
This analysis compares Apotea's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.15x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 22.24x to 9.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | Skr3.33 | Skr74.15 | x |
| 2022-12-31 | Skr3.15 | Skr74.15 | x |
| 2023-12-31 | Skr0.38 | Skr74.15 | x |
| 2024-12-31 | Skr0.54 | Skr74.15 | x |
| 2025-12-31 | Skr8.11 | Skr74.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Apotea utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 27.10%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.17%
- • Asset Turnover: 3.64x
- • Equity Multiplier: 2.35x
- Recent ROE (27.10%) is below the historical average (133.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 30.75% | 2.29% | 4.45x | 3.02x | Skr70.51 Million |
| 2022 | 6.08% | 0.41% | 3.90x | 3.82x | Skr-12.85 Million |
| 2023 | 217.88% | 1.60% | 41.23x | 3.31x | Skr83.01 Million |
| 2024 | 388.13% | 3.29% | 44.65x | 2.65x | Skr209.36 Million |
| 2025 | 27.10% | 3.17% | 3.64x | 2.35x | Skr144.30 Million |
Industry Comparison
This section compares Apotea's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
No peer company data available for comparison.
About Apotea
Apotea AB (publ) operates an online pharmacy in Sweden. The company offers products in the areas of allergy, face, baby, child and parent, bite and sting, preparedness, animal, fever and aches, cold, home and household, aid, hair removal and shaving, hair care, hands and feet, intimate, and dietary supplements. It also provides products in the categories of body care, stomach and intestine, food … Read more